Stock Track | Burning Rock Biotech Soars 5.44% Intraday on Narrowed Losses and Japan Approval

Stock Track

2025/11/28

Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock surge 5.44% during intraday trading on Friday, continuing its recent upward trend. The movement follows the company's latest financial report, which showed a significant narrowing of losses and improved gross margins.

The cancer diagnostics company reported a 75.1% gross margin for Q3, up nearly 4 percentage points year-on-year, alongside a 69% jump in R&D services revenue. Additionally, Burning Rock announced regulatory approval in Japan for its products as companion diagnostics for AstraZeneca's breast cancer drug, capivasertib. These developments have fueled investor optimism, contributing to the stock's rally.

Despite challenges in its core business segments, Burning Rock's improved financial metrics and strategic approvals suggest a potential path to profitability, driving renewed interest in the stock.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1116260561"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116260561\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116260561?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-28 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116260561","market":"us","top_or_hot":-1,"title":"Stock Track | Burning Rock Biotech Soars 5.44% Intraday on Narrowed Losses and Japan Approval","media":"Stock Track","content":"<p>Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock surge 5.44% during intraday trading on Friday, continuing its recent upward trend. The movement follows the company's latest financial report, which showed a significant narrowing of losses and improved gross margins.</p><p>The cancer diagnostics company reported a 75.1% gross margin for Q3, up nearly 4 percentage points year-on-year, alongside a 69% jump in R&D services revenue. Additionally, Burning Rock announced regulatory approval in Japan for its products as companion diagnostics for AstraZeneca's breast cancer drug, capivasertib. These developments have fueled investor optimism, contributing to the stock's rally.</p><p>Despite challenges in its core business segments, Burning Rock's improved financial metrics and strategic approvals suggest a potential path to profitability, driving renewed interest in the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Burning Rock Biotech Soars 5.44% Intraday on Narrowed Losses and Japan Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Burning Rock Biotech Soars 5.44% Intraday on Narrowed Losses and Japan Approval\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-11-28 22:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock surge 5.44% during intraday trading on Friday, continuing its recent upward trend. The movement follows the company's latest financial report, which showed a significant narrowing of losses and improved gross margins.</p><p>The cancer diagnostics company reported a 75.1% gross margin for Q3, up nearly 4 percentage points year-on-year, alongside a 69% jump in R&D services revenue. Additionally, Burning Rock announced regulatory approval in Japan for its products as companion diagnostics for AstraZeneca's breast cancer drug, capivasertib. These developments have fueled investor optimism, contributing to the stock's rally.</p><p>Despite challenges in its core business segments, Burning Rock's improved financial metrics and strategic approvals suggest a potential path to profitability, driving renewed interest in the stock.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNR","symbol_name":"燃石醫學","start_time":0,"source_url":"","article_id":"1116260561","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116260561","pubTimestamp":1764341065,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock surge 5.44% during intraday trading on Friday, continuing its recent upward trend. The movement follows the company's latest financial report,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNR":"燃石医学"},"translate_title":"个股赛道|燃石生物盘中大涨5.44%因跌幅收窄及日本获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNR":1},"content_text":"Burning Rock Biotech Limited (NASDAQ: BNR) saw its stock surge 5.44% during intraday trading on Friday, continuing its recent upward trend. The movement follows the company's latest financial report, which showed a significant narrowing of losses and improved gross margins.The cancer diagnostics company reported a 75.1% gross margin for Q3, up nearly 4 percentage points year-on-year, alongside a 69% jump in R&D services revenue. Additionally, Burning Rock announced regulatory approval in Japan for its products as companion diagnostics for AstraZeneca's breast cancer drug, capivasertib. These developments have fueled investor optimism, contributing to the stock's rally.Despite challenges in its core business segments, Burning Rock's improved financial metrics and strategic approvals suggest a potential path to profitability, driving renewed interest in the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}